Skip to main content
. 2021 Oct 18;7(3):e001838. doi: 10.1136/rmdopen-2021-001838

Figure 2.

Figure 2

Proportions of patients achieving (A) ACR20, (B) ACR50 and (C) ACR70 response at weeks 12, 24 and 56 (NRI). Nominal p values are for upadacitinib versus adalimumab. ACR20/50/70, ≥20%/50%/70% improvement in American College of Rheumatology response criteria; ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; EOW, every other week; NRI, non-responder imputation; PBO, placebo; QD, once daily; UPA, upadacitinib. For the week 56 data, patients originally randomised to placebo switched to either upadacitinib 15 mg QD or upadacitinib 30 mg QD (1:1) at week 24 and their data up to week 24 are under placebo exposure. 95% CIs for response rate were calculated based on normal approximation to the binominal distribution. Nominal p value was constructed using Cochran-Mantel-Haenszel test adjusted for the main stratification factor of current DMARD use (yes/no).